Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($1.11) per share and revenue of $4.2220 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:00 PM ET.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $3.83 million. During the same quarter last year, the company earned ($1.25) EPS. The company’s revenue for the quarter was up 49002.7% compared to the same quarter last year. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Keros Therapeutics Stock Up 1.0%

KROS stock opened at $15.18 on Wednesday. Keros Therapeutics has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm’s 50-day simple moving average is $15.43 and its 200 day simple moving average is $14.52. The stock has a market cap of $462.53 million, a PE ratio of 48.97, a price-to-earnings-growth ratio of 1.94 and a beta of 0.97.

Analyst Ratings Changes

KROS has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company initiated coverage on shares of Keros Therapeutics in a report on Monday, October 20th. They issued an “overweight” rating and a $26.00 price objective on the stock. Finally, HC Wainwright dropped their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Insider Activity

In other Keros Therapeutics news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The SEC filing for this sale provides additional information. 22.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company increased its stake in Keros Therapeutics by 8.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after buying an additional 988 shares during the period. Tower Research Capital LLC TRC increased its stake in Keros Therapeutics by 149.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after buying an additional 2,982 shares during the period. Brevan Howard Capital Management LP increased its stake in Keros Therapeutics by 6.5% during the 2nd quarter. Brevan Howard Capital Management LP now owns 70,149 shares of the company’s stock valued at $936,000 after buying an additional 4,305 shares during the period. Finally, Monimus Capital Management LP grew its stake in shares of Keros Therapeutics by 7.5% in the 2nd quarter. Monimus Capital Management LP now owns 90,396 shares of the company’s stock worth $1,207,000 after purchasing an additional 6,341 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.